skip to navigation skip to content
 

Accelerate

Back to Ventures

These ventures have been with Accelerate Cambridge for over three months and are either looking to finalise their product or close their first sales.

4N Genehealth

Our vision is to develop precision medicine technologies for global healthcare challenges.

Worldwide, diabetes is affecting 425 million people. Globally, healthcare systems spend $727 billion per year to manage people with diabetes. It causes four million deaths per year. In summary, it’s an epidemic that needs to be tackled, and we want to play our part in it.

Diabetes patients have a high risk of developing long-term complications like cardiovascular diseases, retinopathy and some types of cancers. We apply emerging systems biology strategy to patients' blood samples to probe and analyse complex molecular pathways for thousands of biomarkers across genomics, biochemistry, proteomics and metabolomics to determine the personalised risk of long-term complications.

Our system provides a prognostic tool for clinicians to make effective treatment interventions saving healthcare costs and improving patient quality of life.

4N Gene Health logo

Acting Systems™

Acting Systems™ helps social media marketers create original scripts for content by using the demand expressed by audiences on social media. Our solution uses artificial intelligence, machine learning, and content production processes. Each one of our scripts is composed of granular story elements, clearly backed by audience demand.

Visit the Acting Systems website

Acting Systems logo

Antiverse

Antiverse is developing a revolutionary technology to predict antibody drug hits in a single day rather than in months through the traditional methods. A combination of cell-free technology and cutting-edge machine learning is used to develop a proprietary model that recognises and predicts features of antibody-antigen interaction. Ultimately, the customers, who are pharma companies and Contract Research Organisations (CROs), provide us with the sequence of the antigen and Antiverse provides the customers with the sequence of antibodies which bind the antigen with a high affinity. A pharma company and several CROs have already expressed a strong interest in using the service and will also provide support to develop the model as rapidly as possible. Antiverse's technology will greatly speed up antibody hit discovery and thus enable the development of more, and better, antibody therapeutics against cancer, inflammation and rare diseases.  

Antiverse logo

Baby Safe

The 'Safe Sleep Seat' from Baby Safe is a patented, award-winning reclining child car seat for infants from birth to four years.

Controlled simply and quickly at the touch of a wireless button from the driver's position, it ensures full control of the vehicle at all times, avoiding an increased potential for accidents on today's busy roads. It is the first car seat of its kind to address the problem of the 'head flopped forward' position, which can occur while driving as a child sleeps, avoiding airway restriction and preventing positional asphyxia. With an increased risk of airway restriction, and possible neck injuries to a child left in this position, it is quickly and simply resolved at the touch of a wireless button, without the problem of reclining manually, as with all current car seats on the market today. The manual rotation feature reduces awkward positioning for placing a child in the seat, preventing back problems for parents as the child grows.

Visit the Baby Safe website

Baby Safe logo

BioPhonics (formerly TunedIn Dx)

BioPhonics is developing consumer and medical devices to automatically detect abnormalities from bodily sounds. They have developed a prototype of an intelligent stethoscope capable of automatic detection of heart diseases. The company's mission is to produce innovative technology to improve early detection of diseases.

Visit the BioPhonics website

BioPhonics logo

CamDiab

CamDiab is aiming to improve the management of type 1 diabetes and related metabolic disorders. Its product, CamAPS, is an app which connects to a continuous glucose monitor, processes its data and instruct insulin pump to deliver the right amount of insulin reducing the risk of low and high blood glucose levels and reducing the burden of diabetes.

Carryr Technologies

We're on a mission to deliver a rapid and unique experience to fashion e-commerce consumers, making it feel like magic.

We do this by partnering up with city-based fashion retailers so that they can offer their online customers a delivery option that can deliver their orders in as little as an hour and have unwanted items collected without any hassle."

Carryr Technologies logo

CelerX

Coeliac disease is one of the commonest autoimmune conditions affecting the developing world, with one per cent of the population believed to be affected.

Characterised by an intolerance to gluten, there are no medicinal treatments available for the condition and patients adhere to a strict gluten-free diet to ensure the avoidance of symptoms, which include nausea, stomach cramps, and diarrhoea. In spite of this, accidental gluten consumption affects 90 per cent of coeliac patients every month, and correlates to gastrointestinal aberrations in many patients.

At CelerX, we have conceptualised a prophylactic microbiome-based solution that provides constitutive protection against the problem of accidental gluten contamination. Presently, we are leveraging our technology to address unmet medical need in the coeliac disease market, however our ultimate goal is to apply our concept to a multitude of gastrointestinal conditions.

CelerX logo

CropVax

CropVax is a company focussed on improving global agricultural crop productivity while minimising environmental impact. Our technology facilitates the delivery of next generation plant vaccines based on RNAi enabling farmers to treat their crops against destructive pathogens such as viruses or fungi that remain challenging to control with conventional agricultural methods.

Visit the CropVax website

CropVax logo

Heterogeneous

Researchers want dynamic medical and genetic data and people want to participate more directly in research. We have built the heterogeneous platform to allow individuals with genetic data (e.g. from 23andMe) to create a profile and participate directly in ongoing research projects, controlling when and how their data is shared and used. At the same time, we are working directly with rare disease patients and researchers to generate, store, analyze, and share dynamic medical and genetic data used in research and healthcare. We believe that creating a secure, patient-centric marketplace for genetic data will make it easier to conduct genetics research and follow-up studies not only in healthcare, but for a wide variety of organisations.

Visit the Heterogeneous website

Heterogeneous logo

Hyphn Clinical

Clinical trials have been growing increasingly complex for years and despite spiralling costs remain an under-utilised option of health care systems, with only one per cent of the patient population participating in clinical trials and 75 per cent unaware that trials could be an option for treatment. Incorporation of novel technologies to improve the health care system has been incentivised by the government but the uplift hasn't materialised yet and currently, 50 per cent of clinical trials fail to achieve target recruitment and 80 per cent fail to finish on time.

Hyphn Clinical is a digital health platform enabling execution of clinical trials in a smarter, and more efficient way than the traditional "brick-and-mortar" trial conduct model by leveraging three pillars: telemedicine, passive collection of data, and decentralisation of clinical trials. Our product aims to improve execution of clinical trials for investigators while remaining patient-centric by providing a remote access of procedures to patients. Hyphn Clinical is open-source to allow interoperability with other digital products and can be easily installed on any device. Ultimately, Hyphn Clinical is a digital technology enabler. This investigator-focus approach positions Hyphn Clinical with a unique market segment not exploited by the competition with an immediate emphasis on experimental medicine and academic studies.

Hyphn Clinical logo

Kalium Diagnostics

Kalium Diagnostics is developing the world's first blood potassium test suitable for home use. The test will help chronic kidney patients and suffers of rare diseases to manage their health away from hospitals and clinics, improving health and lifestyles and significantly reducing the costs of healthcare provision. Our team combines world-class clinical, scientific and product development expertise.

Visit the Kalium Diagnostics website

Kalium diagnostics logo

Legal Sphere

Legal Sphere is an online legal platform which allows lawyers and their clients to connect and collaborate online. For the clients, the cloud-based offering is a complete end-to-end service which enables legal advice to be personalised, affordable and accessible. For lawyers, it offers a flexible working model which will fall in line with changes to the Solicitors Regulatory Authority guidance which permits freelance work.

Visit the Legal Sphere website

Legal Sphere logo

MAP Innovation

MAP Innovation is a startup company focused on product development primarily within the logistics industry. We are currently developing our own MAP-Ping™ system which is a synergetic product that could also be adapted for other applications.

The system aims to eradicate asset loss and provide customers with an interface that can be utilised to enhance current logistical systems or provide a platform to develop a new one. Our remit was to develop a low cost system that addresses problems associated with similar products, incorporate the latest technology and employ hardware that is reliable, efficient and ideally maintenance free.

MAP Innovation logo

Obsequio Software

More people use Facebook each month than there were humans on the planet 90 years ago. Data privacy regulation is racing to keep pace with how our data is collected and shared. Millions of companies rely on consent from their customers to use their data.

Compliance is a necessary burden. Managing customer consent is complex and expensive. That something requires effort is no excuse for doing it badly.

Removing the obstacles to doing consent well allows companies to focus on their customers.

Obsequio automates the capture and recording of consent, giving both requester and requestee full visibility of what's been agreed to and when, minimising risk and effort.

Obsequio Software logo

Oh Lily! (formerly Water LilyPop)

We believe that eating is a necessity, but to eat intelligently is an art!

Oh Lily! is a range of sweet and savoury snacks made from water lily seeds. Water lily seeds have been used for centuries in traditional medicines such as Ayurveda and Chinese medicine for its high nutritional values. Still unknown in the western world, the potential of this plant is underutilised, and we aim to share the benefits of these seeds with our consumers, convinced that it will bring a snacking revolution. Indeed, more and more people are deciding to change their way of eating and choosing different diets. Health has become a priority, but the consumer doesn't want to compromise on the taste, fun or texture. With its snacks, Oh Lily! is gathering all of those criteria to offer a healthy, tasty and crunchy experience. The seeds are naturally gluten-free and free from sugar and all our recipes are vegan, so Oh Lily! fits for all and is good for all.

In our project we aim to work closely with the local farmers and participate to the improvement of their livelihood, we would like to contribute to a more sustainable future for the food industry in term of product, packaging and supply chain.

Our mission is to take the consumer on a conscious culinary journey.

Oh Lily! logo

Orca Scan

Barcode technology first made its impact on business productivity in the late 1970s, yet due to the complexity and high costs associated with implementing enterprise barcode solutions, the majority of organisations still rely on pen, paper and spreadsheets to manage their assets and inventory.

 

Orca Scan was designed to dramatically simplify, and lower the cost of enterprise barcode solutions to make barcode tracking technology available to all, regardless of company size or budget. They do that by removing the need for expensive hardware and custom software development, by leveraging cloud computing and the smartphone we're all carrying in our pockets.

 

Visit the Orca Scanwebsite

Orca Scan logo

Outfield

Outfield is providing farmers with access to new drone technologies. We are developing a range of innovative services using autonomous aircraft and computer vision systems. Outfield services range from land surveying to horticulture crop management, using systems that are faster, cheaper and more accurate than current field assessment techniques. Outfield is growing the future of precision farming.

Visit the Outfield website

Outfield logo

Pentail Enzymes

We are a biotechnology company harnessing the power of enzymes to improve human health. Pentail's primary goal is to engineer and produce enzymes that target harmful substances in the human body for rapid elimination. Our prototype enzymes are being developed to neutralise a range of misused drugs, including prescription and over-the-counter medicines, which when overdosed can often lead to death or permanent organ damage. As the incidence of drug intoxication reaches epidemic levels worldwide, with significant health and social costs, our technology will provide an accessible tool for emergency services, ultimately helping to save lives.

Pentail Enzymes logo

POCKiT diagnostics

POCKiT diagnostics is a UK- and Ireland-based startup company aimed at improving diagnosis of brain stroke. Stroke is the third leading cause of death in the Western world and the first cause of physical disability and dementia in adults. Every year 15 million people in the world suffer a stroke; of these, five million die and another five million suffer permanent disability as a consequence of the stroke. Events of brain stroke can occur upon blockage or rupture of blood vessels, giving rise to ischemic stroke (AIS) or intracerebral haemorrhage (ICH), respectively. Patients suffering from AIS or ICH are treated with thrombolytic or pro-coagulant therapy, respectively. Early and reliable diagnosis of the type of stroke is fundamental, as a very narrow time window (four and a half hours) is available for the treatment to be delivered before brain damage becomes permanent. Accurate diagnosis of stroke is paramount, as erroneous administration of thrombolytic or pro-coagulant agents can lead to permanent disability or death. Currently, diagnosis of stroke is performed with computed tomography (CT), which has a high sensitivity for the diagnosis of ICH, but not of AIS. Moreover, CT takes valuable time and is not always readily available in emergency situations, thus delaying treatment of stroke patients and increasing the risk of stroke morbidity and mortality. 

So how is POCKiT going to improve this? After an ischemic or haemorrhagic stroke, specific molecules (biomarkers) are released into our blood. POCKiT is developing a diagnostic device for the rapid diagnosis of AIS and ICH patients. Our innovation is the application of rapid immune-based detection of stroke-specific biomarkers to provide diagnosis of stroke in less than 20 minutes. This diagnostic application can be operated by anyone without the use of laboratory equipment, or individuals trained in chemical analysis. Moreover, our device will be very cheap and highly portable, being able to fit in your pocket. In contrast with other diagnostic tools for stroke that deploy individual or small sets of biomarkers for stroke diagnosis, our device can detect up to 10 different biomarkers, thus significantly improving specificity and sensitivity of diagnosis. We have developed a panel of positive and negative biomarkers for AIS and ICH, potentially allowing to distinguish these conditions univocally. The combination of a rapid diagnostic device, together with our unique panel of stroke subtype-specific biomarkers will allow accurate, fast and cheap diagnosis of stroke patients, potentially leading to faster treatment and reducing disability and death of stroke patients.

Pockit diagnostics logo

Qureight

Qureight is a clinical data curation and analytics company which works in partnership with healthcare bodies and software developers in the field of artificial intelligence. 

Through advanced infrastructure, coupled with technical and clinical expertise, the company performs annotation and analysis of anonymised data. Qureight exploits the value of data in their entirety and allows testing of machine learning algorithms, by collaborating with drug or technology companies, healthcare and academic institutions.

Qureight's mission is to combine technology and life sciences to generate new knowledge and transform the way we use clinical data.

Qureight logo

Scope

The news we read is heavily biased towards negative clickbait, stories about death and scandal are commonplace and overshadow lots of interesting coverage. Good journalism about current affairs and new technologies is often missed even though it is highly relevant and more beneficial. News providers use negative news to craft big headlines, exploiting human psychology to draw people in. This leads to a disproportionate number of negative stories biasing the news. For example, journalism about how Germany manages to run a budget surplus will never be shown on the BBC homepage.

Scope aggregates news and uses machine learning to automatically detect and reduce the visibility of negative clickbait. The platform, accessible via mobile, tablet and desktop, is delivered through a website and native Android and iOS applications. Scope loads live articles from all major news providers and employees a probabilistic approach to suppress negative clickbait using cutting edge recurrent neural networks. A user enters their favourite news topics and sources, allowing the platform to provide them with a custom-built news feed post filtering; resulting in relevant and previously overshadowed articles being brought to the forefront.

Visit the Scope website

Scope logo

Spliceor Therapeutics

Spliceor Therapeutics is an early stage research and development biotechnology company based on translational medical research in Professor Andrew Lever's laboratory in the Department of Medicine, University of Cambridge.

Co-founded by Dr Carin Ingemarsdotter and Professor Lever, the proposed business aims at developing novel curative treatments for certain types of aggressive cancers that do not respond well to current treatment. Our therapeutics are based on a gene-therapy platform technology and we have identified a common mechanism for therapeutic development against liver cancer and pancreatic cancer, successful treatment of which are major unmet medical needs. Our technology is applicable to many other malignancies. Our mission is to provide curative and easily tolerated gene therapies to cancer patients.

Sliceor Therapeutics logo

Tinker Design

Tinker Design, a wearable technology company addressing health, wellness and comfort. Athena, by Tinker is a smart interactive massage shoe controlled via your smartphone for a customised massage on your feet. The sensor technology allows the user to measure feedback and customise different massage sensations. It is personalised to transform your wellbeing to help optimise your lifestyle for healthy living - engaging each individual in an inherently personal way.

Tinker Design logo

typewise

typewise is an online platform that promotes efficient translation services tailored specifically to academic needs. By connecting customers to a core group of University of Cambridge students, we ensure high quality assistance at competitive prices. With a range of over 50 languages and representation in over 100 subject areas, we connect customers to individual students that can provide excellent service with specialised expertise and high language proficiency.

With typewise, we want to connect people, especially academics, to a close-knitted community that knows no boundaries for communication.

typewise logo

Uverify

With fraudulent certificates and degrees being increasingly accessible for purchase online, educational institutions, learners, and employers alike are finding it expensive and time-consuming to verify the authenticity of certificates. Paper-based certificates are also vulnerable to loss or damage. The current systems and record keeping processes are fragmented. Holders of certificates have to deal with multiple institutions, often with different processes, digital systems and agencies to manage and verify them.

Uverify is an instant verification tool that is powered by blockchain technology that addresses these issues. We enable learners to manage and take ownership of their lifetime record of certificates and other professional qualifications. Certificates issued by institutions are digital, instantly verifiable, immutable, and secure. Our digital passport creates a single profile view of the learner’s fragmented credentials. Uverify helps institutions combat fraud and saves them time and money by automating the verification process.

Uverify logo